Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
Healthcare
$6.70 -2.18%
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
52W Low $4.50High $24.27
Volume 1.58M
Average 1.61M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$51.46M
FY 2025 · Annual
Investing Cash Flow
-$81.72M
FY 2025 · Annual
Financing Cash Flow
$14.59M
FY 2025 · Annual
-91.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| Deferred Income Tax | 22K | 28K | 14K | 114K | 165K |
| Stock-Based Compensation | 8.17M | 7.55M | 3.48M | 5.85M | 13.62M |
| Change in Working Capital | 2.84M | (60K) | (9.24M) | (4.71M) | 3.84M |
| Accounts Receivables | 1.12M | 2.88M | 1.78M | (475K) | 0 |
| Inventory | (35K) | 18K | 20K | 0 | 0 |
| Accounts Payables | 796K | (487K) | (2.44M) | (163K) | (146K) |
| Other Working Capital | 961K | (2.47M) | (8.61M) | (4.07M) | 3.99M |
| Other Non-Cash Items | 794K | 7.22M | 6.46M | (15.35M) | 8.83M |
| Operating Cash Flow | (70.89M) | (26.75M) | (30.68M) | (49.06M) | (51.46M) |
| Capital Expenditures | (113K) | (95K) | (158K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 356K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (113.72M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 31.31M |
| Other Investing Activities | 0 | 0 | 25K | 0 | 690K |
| Investing Cash Flow | (113K) | (95K) | (133K) | 356K | (81.72M) |
| Debt Repayment | 32.9M | (14.81M) | (21.24M) | 0 | 0 |
| Common Stock Issued | 71.93M | 107K | 46.22M | 115.63M | 15.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.93M | 0 | 67K | 60.22M | (510K) |
| Financing Cash Flow | 106.76M | (14.7M) | 25.04M | 175.85M | 14.59M |
| Effect of Forex Changes | 0 | 96K | 0 | 0 | 0 |
| Net Change in Cash | 35.76M | (41.45M) | (5.77M) | 127.15M | (118.59M) |
| Free Cash Flow | (71.01M) | (26.85M) | (30.84M) | (49.06M) | (51.46M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$78.3M
+ D&A$344.0K
+ Stock-Based Comp$13.6M
+ Deferred Tax$165.0K
+ Working Capital$3.8M
+ Other Non-Cash$8.8M
= Operating Cash Flow-$51.5M
- Capex$0
= Free Cash Flow-$51.5M
Analysis
FY2025 free cash flow is -$51.5M. FCF conversion is 65.8% of net income. Operating cash flow was -$51.5M, with capex of $0. The largest bridge item is Stock-Based Comp at $13.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 |
Does AVTX generate free cash flow?
Avalo Therapeutics, Inc. (AVTX) generated -$51.46M of free cash flow in fiscal 2025.
How much operating cash flow does AVTX produce?
Operating cash flow was -$51.46M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.